

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GOLDEN MEDITECH HOLDINGS LIMITED

金衛醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 00801)

CHANGE IN BOARD LOT SIZE

Reference is made to (i) the scheme document dated 21 August 2020 jointly issued by the Company and Meditech Global Group Limited (the “**Offeror**”) in relation to, among other things, the proposed privatisation of the Company by the Offeror by way of a scheme of arrangement (under section 86 of the Companies Law, Cap. 22 (Law 3 of 1961), as consolidated and revised, of the Cayman Islands) and the proposed withdrawal of listing of the shares of the Company from The Stock Exchange of Hong Kong Limited (the “**Scheme Document**”); and (ii) the results announcement dated 16 September 2020 jointly issued by the Company and the Offeror in relation to the results of the Court Meeting and the General Meeting (the “**Results Announcement**”). Unless the context requires otherwise, capitalised terms used herein shall have the same meanings as those defined in the Scheme Document.

CHANGE IN BOARD LOT SIZE

The Board announces that the board lot size of the Shares will be changed from 4,000 Shares to 800,000 Shares with effect from Thursday, 24 September 2020.

REASONS FOR AND BENEFITS OF THE CHANGE IN BOARD LOT SIZE

As set out in the Scheme Document, on 17 June 2020, the Offeror and the Company jointly announced that on 9 June 2020, the Offeror had requested the Board to put forward the Proposal to the Scheme Shareholders for the privatisation of the Company by way of a scheme of arrangement under Section 86 of the Companies Law of the Cayman Islands involving, among other things, the cancellation of the Disinterested Scheme Shares and, in consideration thereof, the payment to the Scheme Shareholders of the Cancellation Price in cash for each Disinterested Scheme Share, and the withdrawal of the listing of the Shares on the Stock Exchange.

As set out in the Results Announcement, the Court Meeting and the General Meeting were held on Wednesday, 16 September 2020, during which all relevant resolutions in relation to the Proposal and the Scheme were duly approved by the Scheme Shareholders or Shareholders (as the case may be) in accordance with the relevant requirements under the Takeovers Code and the Companies Law of the Cayman Islands.

The Company has applied to the Stock Exchange for the withdrawal of the listing of the Shares from the Stock Exchange in accordance with Rule 6.15(2) of the Listing Rules, subject to, among other things, the sanction of the Scheme (with or without modifications) by the Grand Court and all other Conditions having been fulfilled or waived, as applicable. Subject to the Proposal and the Scheme becoming effective on the Effective Date, the listing of the Shares on the Stock Exchange is expected to be withdrawn at 4:00 p.m. on Friday, 16 October 2020.

As set out in the section headed “PART III. EXPECTED TIMETABLE” in the Scheme Document, the latest time for trading in the Shares on the Stock Exchange is expected to be 4:10 p.m. on Wednesday, 23 September 2020. The change in board lot size of the Shares will only become effective after the latest time for trading in the Shares on the Stock Exchange.

The new board lot size of 800,000 Shares is determined after taking into account the maximum board lot size permitted under the Listing Rules and the relevant guidance issued by the Stock Exchange, with a view to minimising the number of board lots of Shares held by the Shareholders. The change in board lot size of the Shares will benefit the Shareholders by way of minimising the administrative expenses involved in the privatisation process.

For the avoidance of doubt, the change in board lot size of the Shares would not, subject to the Proposal and the Scheme becoming effective, affect the entitlements of the Scheme Shareholders under the Scheme (including the Cancellation Price).

EXPECTED TIMETABLE FOR THE CHANGE IN BOARD LOT SIZE

Effective date of the change in board lot size

from 4,000 Shares to 800,000 Shares. Thursday, 24 September 2020

ODD LOT MATCHING AND PARALLEL TRADING ARRANGEMENTS

The latest time for trading in the Shares on the Stock Exchange is expected to be 4:10 p.m. on Wednesday, 23 September 2020. It is expected that trading in the Shares on the Stock Exchange will be suspended from the said date and time and up to the date of withdrawal of the listing of the Shares on the Stock Exchange becoming effective (which is expected to be at 4:00 p.m. on Friday, 16 October 2020). In addition, subject to the Proposal and the Scheme becoming effective, the Disinterested Scheme Shares held by the Disinterested Shareholders (including any Disinterested Scheme Shares held by odd lot holders) will be cancelled on the Effective Date. As such, the Board is of the view that it is reasonable and expedient not to arrange for any odd lot matching services to the Shareholders. There will be no parallel trading arrangement.

ARRANGEMENT ON SHARE CERTIFICATES

All existing share certificates in board lot of 4,000 Shares will continue to be evidence of title to such Shares and be valid for delivery, transfer and settlement purposes. Therefore, no exchange of existing share certificates will be required and no arrangement for free exchange of existing share certificates will be provided.

By order of the board of
Golden Meditech Holdings Limited
Feng Wen
Executive Director

Hong Kong, 17 September 2020

As at the date of this announcement, the Board comprises five Directors. The executive Directors are Mr. Feng Wen (Chairman) and Mr. Leong Kim Chuan (Chief Executive); and the independent non-executive Directors are Mr. Gao Yue, Mr. Poon Tsz Hang and Mr. Daniel Foa.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable inquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statement in this announcement misleading.